Outcome of Board Meeting held today i.e., Friday, 13th February, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hemo Organic Limited's Board approved unaudited standalone financial results for Q3 FY26 and nine months ended December 31, 2025. Revenue from operations collapsed to just Rs. 0.01 lakh in Q3 FY26 from Rs. 6.99 lakh in Q3 FY25, and nine-month revenue fell to Rs. 0.40 lakh from Rs. 248.42 lakh a year ago. The company reported a loss after tax of Rs. 3.09 lakh for the quarter and Rs. 27.24 lakh for nine months, versus losses of Rs. 0.79 lakh and Rs. 3.35 lakh in the corresponding prior-year periods. Diluted EPS stood at Rs. (0.23) for Q3 and Rs. (0.79) for nine months. The statutory auditor (MAAK & Associates) issued a qualified review report, stating they were not provided balance confirmations or supporting details for trade receivables and trade payables.
The stock is clearly a very small, thinly-traded company that has effectively lost its operating revenue base, with widening losses and an auditor qualification flagging gaps in receivables/payables verification—raising concerns about book quality and going-concern viability for retail shareholders.